[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fS5hch1k7OUXp8Rm_WOh3k8dA2NtCIUYFkKAAjDakFhk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"Population Health Research Institute",[4],115,false,31,37,495343,20,56,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Atrial Fibrillation",22,{"name":18,"count":19},"Stroke",9,{"name":21,"count":22},"Heart Failure",7,{"name":24,"count":25},"Myocardial Infarction",6,{"name":27,"count":28},"Cardiovascular Diseases",5,{"name":30,"count":28},"Type 2 Diabetes Mellitus",{"name":32,"count":33},"Coronary Artery Disease",4,{"name":35,"count":33},"Ischemic Stroke",[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04049591","Higher vs. Lower Dose Heparin for PCI","2024-10-08","Higher Dose UFH",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04876950","Post Discharge After Surgery Virtual Care with Remote Automated Monitoring Technology-2 (PVC-RAM-2) Trial","2025-12","Virtual care with remote automated monitoring",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04680442","Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction","2025-12-31","Trastuzumab",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT03950076","EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)","2026-05-13","Edoxaban",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05102123","PeRiopEratiVE SmokiNg CessaTion Trial","2026-07-01","Cytisine",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT03636295","Low INR to Minimize Bleeding With Mechanical Valves Trial","2026-12-31","Warfarin",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT07011095","DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial","2027-02-03","VKA",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04284839","The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial","2027-06","DOAC",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT07511543","Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy","2028-06-30","Semaglutide",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT06587737","Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage","2028-07-30","Colchicine 0.5 MG",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,119,144,184,216,276,307,330,356,378,403,421,439,458,481,499,517,535,558,580,598,668,731,768,819,868,890,925,952,970,995,1019,1037,1063,1081,1110,1128,1151,1169,1187,1205,1247,1281,1309,1333,1351,1369,1387,1405,1431,1449,1474,1502,1520,1538,1556,1574,1592,1617,1645,1663,1681,1699,1723,1741,1759,1777,1803,1821,1844,1871,1889,1918],{"intervention":56,"totalTrials":96,"cells":97},1,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":117},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":96,"soonestReadout":55},[109],{"nctId":53,"briefTitle":54,"status":110,"phases":111,"primaryCompletion":55,"completion":55,"start":112,"enrollment":113,"conditions":114,"interventions":116},"ACTIVE_NOT_RECRUITING",[92],"2019-09-20",948,[115,15],"Intracranial Hemorrhages",[56],{"trials":118,"activeCount":100},[],{"intervention":120,"totalTrials":96,"cells":121},"Non-vitamin K oral anticoagulant",{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":142},{"trials":123,"activeCount":100},[],{"trials":125,"activeCount":100},[],{"trials":127,"activeCount":100},[],{"trials":129,"activeCount":100},[],{"trials":131,"activeCount":96,"soonestReadout":137},[132],{"nctId":133,"briefTitle":134,"status":135,"phases":136,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":141},"NCT03968393","Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress","RECRUITING",[92],"2028-12","2019-06-14",2270,[18,15],[120],{"trials":143,"activeCount":100},[],{"intervention":86,"totalTrials":145,"cells":146},2,{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":180,"NA":182},{"trials":148,"activeCount":100},[],{"trials":150,"activeCount":100},[],{"trials":152,"activeCount":100},[],{"trials":154,"activeCount":145,"soonestReadout":85},[155,166],{"nctId":83,"briefTitle":84,"status":156,"phases":157,"primaryCompletion":85,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":165},"NOT_YET_RECRUITING",[91],"2028-10-30","2026-05-30",1125,[162,163,18,164],"Colchicine","ICH - Intracerebral Hemorrhage","Dependence",[86],{"nctId":167,"briefTitle":168,"status":135,"phases":169,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":177},"NCT04774159","Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk",[91],"2029-12","2021-05-06",6150,[174,175,176],"Peripheral Arterial Disease","Atherosclerosis of Extremities","Inflammation",[178,179],"Colchicine 0.5 MG Oral","Colchicine-Placebo",{"trials":181,"activeCount":100},[],{"trials":183,"activeCount":100},[],{"intervention":71,"totalTrials":145,"cells":185},{"EARLY_PHASE1":186,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":212,"NA":214},{"trials":187,"activeCount":96,"soonestReadout":70},[188],{"nctId":68,"briefTitle":69,"status":156,"phases":189,"primaryCompletion":70,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":196},[88],"2027-06-03","2025-09-03",100,[194,195],"Atrial Fibrillation (AF)","Stroke (in Patients With Atrial Fibrillation)",[71,197],"Direct Oral Anticoagulant",{"trials":199,"activeCount":100},[],{"trials":201,"activeCount":100},[],{"trials":203,"activeCount":96,"soonestReadout":75},[204],{"nctId":73,"briefTitle":74,"status":135,"phases":205,"primaryCompletion":75,"completion":75,"start":206,"enrollment":207,"conditions":208,"interventions":211},[91],"2021-07-18",3500,[209,210],"Bleeding Post Cardiac Surgery","Indication for Anticoagulation",[76,71],{"trials":213,"activeCount":100},[],{"trials":215,"activeCount":100},[],{"intervention":217,"totalTrials":33,"cells":218},"Rivaroxaban",{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":272,"NA":274},{"trials":220,"activeCount":100},[],{"trials":222,"activeCount":100},[],{"trials":224,"activeCount":100},[],{"trials":226,"activeCount":96,"soonestReadout":266},[227,241,252,262],{"nctId":228,"briefTitle":229,"status":230,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":238},"NCT04324463","Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial","COMPLETED",[91],"2022-12-30","2020-04-21",6667,[236,237],"Coronavirus","Severe Acute Respiratory Syndrome",[162,239,240,217],"Interferon-Beta","Aspirin",{"nctId":242,"briefTitle":243,"status":230,"phases":244,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},"NCT02832544","INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority",[91],"2022-08-18","2016-08-22",4565,[249],"Rheumatic Heart Disease",[217,251],"Vitamin K antagonists",{"nctId":253,"briefTitle":254,"status":255,"phases":256,"primaryCompletion":257,"completion":258,"start":259,"enrollment":100,"conditions":260,"interventions":261},"NCT02832531","INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority","WITHDRAWN",[91],"2022-04","2022-08","2022-01",[249],[217,240],{"nctId":263,"briefTitle":264,"status":156,"phases":265,"primaryCompletion":266,"completion":266,"start":159,"enrollment":267,"conditions":268,"interventions":270},"NCT07468448","Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)",[91],"2029-12-30",1172,[35,269],"Intracranial Atherosclerosis",[217,271],"ASA",{"trials":273,"activeCount":100},[],{"trials":275,"activeCount":100},[],{"intervention":179,"totalTrials":145,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":303,"NA":305},{"trials":279,"activeCount":100},[],{"trials":281,"activeCount":100},[],{"trials":283,"activeCount":100},[],{"trials":285,"activeCount":96,"soonestReadout":170},[286,299],{"nctId":287,"briefTitle":288,"status":230,"phases":289,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":296},"NCT03048825","Colchicine and Spironolactone in Patients with MI \u002F SYNERGY Stent Registry",[91],"2024-08-09","2018-02-01",7264,[294,295],"ST Elevation Myocardial Infarction","Non ST Elevation Myocardial Infarction",[162,297,179,298],"Spironolactone","Spironolactone-Placebo",{"nctId":167,"briefTitle":168,"status":135,"phases":300,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":301,"interventions":302},[91],[174,175,176],[178,179],{"trials":304,"activeCount":100},[],{"trials":306,"activeCount":100},[],{"intervention":61,"totalTrials":96,"cells":308},{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":326,"NA":328},{"trials":310,"activeCount":100},[],{"trials":312,"activeCount":100},[],{"trials":314,"activeCount":100},[],{"trials":316,"activeCount":96,"soonestReadout":60},[317],{"nctId":58,"briefTitle":59,"status":110,"phases":318,"primaryCompletion":60,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":325},[91],"2027-01-01","2024-01-15",1720,[323,324],"Smoking (Tobacco) Addiction","Smoking Cessation",[61],{"trials":327,"activeCount":100},[],{"trials":329,"activeCount":100},[],{"intervention":331,"totalTrials":96,"cells":332},"Amiodarone Hydrochloride 200 MG",{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":337,"PHASE3":339,"PHASE4":352,"NA":354},{"trials":334,"activeCount":100},[],{"trials":336,"activeCount":100},[],{"trials":338,"activeCount":100},[],{"trials":340,"activeCount":96,"soonestReadout":345},[341],{"nctId":342,"briefTitle":343,"status":135,"phases":344,"primaryCompletion":345,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":351},"NCT05841056","Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial",[91],"2028-08-31","2028-11-30","2024-06-13",400,[350],"Atrial Fibrillation New Onset",[331],{"trials":353,"activeCount":100},[],{"trials":355,"activeCount":100},[],{"intervention":66,"totalTrials":96,"cells":357},{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":374,"NA":376},{"trials":359,"activeCount":100},[],{"trials":361,"activeCount":100},[],{"trials":363,"activeCount":100},[],{"trials":365,"activeCount":96,"soonestReadout":65},[366],{"nctId":63,"briefTitle":64,"status":135,"phases":367,"primaryCompletion":65,"completion":65,"start":368,"enrollment":369,"conditions":370,"interventions":373},[91],"2019-09-05",2625,[371,372],"Bleeding Post-mechanical Valve Replacement","Thromboembolism Post-mechanical Valve Replacement",[66],{"trials":375,"activeCount":100},[],{"trials":377,"activeCount":100},[],{"intervention":379,"totalTrials":96,"cells":380},"Azithromycin Oral",{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":387,"PHASE4":399,"NA":401},{"trials":382,"activeCount":100},[],{"trials":384,"activeCount":100},[],{"trials":386,"activeCount":100},[],{"trials":388,"activeCount":96,"soonestReadout":346},[389],{"nctId":390,"briefTitle":391,"status":135,"phases":392,"primaryCompletion":346,"completion":393,"start":394,"enrollment":395,"conditions":396,"interventions":398},"NCT05580666","Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)",[91],"2029-05-31","2023-05-08",8000,[397],"HIV Disease Progression",[379],{"trials":400,"activeCount":100},[],{"trials":402,"activeCount":100},[],{"intervention":271,"totalTrials":96,"cells":404},{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":411,"PHASE4":417,"NA":419},{"trials":406,"activeCount":100},[],{"trials":408,"activeCount":100},[],{"trials":410,"activeCount":100},[],{"trials":412,"activeCount":96,"soonestReadout":266},[413],{"nctId":263,"briefTitle":264,"status":156,"phases":414,"primaryCompletion":266,"completion":266,"start":159,"enrollment":267,"conditions":415,"interventions":416},[91],[35,269],[217,271],{"trials":418,"activeCount":100},[],{"trials":420,"activeCount":100},[],{"intervention":76,"totalTrials":96,"cells":422},{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":429,"PHASE4":435,"NA":437},{"trials":424,"activeCount":100},[],{"trials":426,"activeCount":100},[],{"trials":428,"activeCount":100},[],{"trials":430,"activeCount":96,"soonestReadout":75},[431],{"nctId":73,"briefTitle":74,"status":135,"phases":432,"primaryCompletion":75,"completion":75,"start":206,"enrollment":207,"conditions":433,"interventions":434},[91],[209,210],[76,71],{"trials":436,"activeCount":100},[],{"trials":438,"activeCount":100},[],{"intervention":81,"totalTrials":96,"cells":440},{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":452,"PHASE4":454,"NA":456},{"trials":442,"activeCount":100},[],{"trials":444,"activeCount":100},[],{"trials":446,"activeCount":96,"soonestReadout":80},[447],{"nctId":78,"briefTitle":79,"status":156,"phases":448,"primaryCompletion":80,"completion":80,"start":449,"enrollment":192,"conditions":450,"interventions":451},[90],"2026-06-30",[35],[81],{"trials":453,"activeCount":100},[],{"trials":455,"activeCount":100},[],{"trials":457,"activeCount":100},[],{"intervention":51,"totalTrials":96,"cells":459},{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":475,"PHASE4":477,"NA":479},{"trials":461,"activeCount":100},[],{"trials":463,"activeCount":100},[],{"trials":465,"activeCount":96,"soonestReadout":50},[466],{"nctId":48,"briefTitle":49,"status":135,"phases":467,"primaryCompletion":50,"completion":449,"start":468,"enrollment":469,"conditions":470,"interventions":472},[90],"2021-07-01",130,[471,21],"Breast Cancer",[51,473,474],"Pertuzumab","Trastuzumab emtansine",{"trials":476,"activeCount":100},[],{"trials":478,"activeCount":100},[],{"trials":480,"activeCount":100},[],{"intervention":473,"totalTrials":96,"cells":482},{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":493,"PHASE4":495,"NA":497},{"trials":484,"activeCount":100},[],{"trials":486,"activeCount":100},[],{"trials":488,"activeCount":96,"soonestReadout":50},[489],{"nctId":48,"briefTitle":49,"status":135,"phases":490,"primaryCompletion":50,"completion":449,"start":468,"enrollment":469,"conditions":491,"interventions":492},[90],[471,21],[51,473,474],{"trials":494,"activeCount":100},[],{"trials":496,"activeCount":100},[],{"trials":498,"activeCount":100},[],{"intervention":474,"totalTrials":96,"cells":500},{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":511,"PHASE4":513,"NA":515},{"trials":502,"activeCount":100},[],{"trials":504,"activeCount":100},[],{"trials":506,"activeCount":96,"soonestReadout":50},[507],{"nctId":48,"briefTitle":49,"status":135,"phases":508,"primaryCompletion":50,"completion":449,"start":468,"enrollment":469,"conditions":509,"interventions":510},[90],[471,21],[51,473,474],{"trials":512,"activeCount":100},[],{"trials":514,"activeCount":100},[],{"trials":516,"activeCount":100},[],{"intervention":197,"totalTrials":96,"cells":518},{"EARLY_PHASE1":519,"PHASE1":525,"PHASE2":527,"PHASE3":529,"PHASE4":531,"NA":533},{"trials":520,"activeCount":96,"soonestReadout":70},[521],{"nctId":68,"briefTitle":69,"status":156,"phases":522,"primaryCompletion":70,"completion":190,"start":191,"enrollment":192,"conditions":523,"interventions":524},[88],[194,195],[71,197],{"trials":526,"activeCount":100},[],{"trials":528,"activeCount":100},[],{"trials":530,"activeCount":100},[],{"trials":532,"activeCount":100},[],{"trials":534,"activeCount":100},[],{"intervention":46,"totalTrials":96,"cells":536},{"EARLY_PHASE1":537,"PHASE1":539,"PHASE2":541,"PHASE3":543,"PHASE4":545,"NA":547},{"trials":538,"activeCount":100},[],{"trials":540,"activeCount":100},[],{"trials":542,"activeCount":100},[],{"trials":544,"activeCount":100},[],{"trials":546,"activeCount":100},[],{"trials":548,"activeCount":96,"soonestReadout":45},[549],{"nctId":43,"briefTitle":44,"status":135,"phases":550,"primaryCompletion":45,"completion":551,"start":552,"enrollment":553,"conditions":554,"interventions":557},[93],"2026-03","2024-10-04",2000,[555,556],"Surgery","Perioperative Complication",[46],{"intervention":41,"totalTrials":96,"cells":559},{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":570},{"trials":561,"activeCount":100},[],{"trials":563,"activeCount":100},[],{"trials":565,"activeCount":100},[],{"trials":567,"activeCount":100},[],{"trials":569,"activeCount":100},[],{"trials":571,"activeCount":96,"soonestReadout":40},[572],{"nctId":38,"briefTitle":39,"status":135,"phases":573,"primaryCompletion":40,"completion":45,"start":574,"enrollment":575,"conditions":576,"interventions":578},[93],"2022-03-02",16000,[27,577],"Percutaneous Coronary Intervention",[41,579],"Lower Dose UFH",{"intervention":579,"totalTrials":96,"cells":581},{"EARLY_PHASE1":582,"PHASE1":584,"PHASE2":586,"PHASE3":588,"PHASE4":590,"NA":592},{"trials":583,"activeCount":100},[],{"trials":585,"activeCount":100},[],{"trials":587,"activeCount":100},[],{"trials":589,"activeCount":100},[],{"trials":591,"activeCount":100},[],{"trials":593,"activeCount":96,"soonestReadout":40},[594],{"nctId":38,"briefTitle":39,"status":135,"phases":595,"primaryCompletion":40,"completion":45,"start":574,"enrollment":575,"conditions":596,"interventions":597},[93],[27,577],[41,579],{"intervention":240,"totalTrials":25,"cells":599},{"EARLY_PHASE1":600,"PHASE1":602,"PHASE2":604,"PHASE3":606,"PHASE4":631,"NA":666},{"trials":601,"activeCount":100},[],{"trials":603,"activeCount":100},[],{"trials":605,"activeCount":100},[],{"trials":607,"activeCount":100},[608,612,627],{"nctId":228,"briefTitle":229,"status":230,"phases":609,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":610,"interventions":611},[91],[236,237],[162,239,240,217],{"nctId":613,"briefTitle":614,"status":230,"phases":615,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":620,"interventions":624},"NCT01646437","The International Polycap Study 3 (TIPS-3)",[91],"2020-06-30","2021-08-30","2012-06",7793,[621,622,623],"Cardiovascular Disease","Fractures","Cancers",[625,240,626],"Polycap","Vitamin D",{"nctId":253,"briefTitle":254,"status":255,"phases":628,"primaryCompletion":257,"completion":258,"start":259,"enrollment":100,"conditions":629,"interventions":630},[91],[249],[217,240],{"trials":632,"activeCount":100},[633,644,656],{"nctId":634,"briefTitle":635,"status":230,"phases":636,"primaryCompletion":637,"completion":638,"start":639,"enrollment":640,"conditions":641,"interventions":642},"NCT01102439","Clopidogrel\u002FAspirin Interaction Study",[92],"2010-12","2013-02","2010-04",82,[32],[643,643,240,240],"Clopidogrel",{"nctId":645,"briefTitle":646,"status":230,"phases":647,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":652,"interventions":653},"NCT01938248","Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation",[92],"2023-10-27","2023-11-03","2015-05",4012,[15,18],[654,655],"Apixaban","aspirin",{"nctId":657,"briefTitle":658,"status":230,"phases":659,"primaryCompletion":660,"completion":660,"start":661,"enrollment":662,"conditions":663,"interventions":665},"NCT01341964","Clopidogrel and Aspirin Interaction Study-2",[92],"2013-04","2011-05",302,[664],"Drug Action Increased",[643,240,240],{"trials":667,"activeCount":100},[],{"intervention":669,"totalTrials":33,"cells":670},"Metformin",{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":703,"NA":729},{"trials":672,"activeCount":100},[],{"trials":674,"activeCount":100},[],{"trials":676,"activeCount":100},[],{"trials":678,"activeCount":100},[679,691],{"nctId":680,"briefTitle":681,"status":230,"phases":682,"primaryCompletion":683,"completion":684,"start":685,"enrollment":686,"conditions":687,"interventions":688},"NCT03862716","Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira",[91],"2022-06-15","2023-07-31","2019-04-23",159,[30],[689,690,669],"IDegLira","insulin degludec",{"nctId":692,"briefTitle":693,"status":230,"phases":694,"primaryCompletion":695,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":700},"NCT03130426","Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi",[91],"2019-06-30","2020-09-30","2017-06-27",161,[30],[701,702,669],"iGlarLixi","Insulin Glargine",{"trials":704,"activeCount":100},[705,718],{"nctId":706,"briefTitle":707,"status":230,"phases":708,"primaryCompletion":709,"completion":710,"start":711,"enrollment":712,"conditions":713,"interventions":714},"NCT02561130","Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga",[92],"2017-07","2018-12-31","2015-12",154,[30],[715,716,717],"insulin glargine","metformin","Forxiga",{"nctId":719,"briefTitle":720,"status":230,"phases":721,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":727},"NCT01181674","Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)",[92],"2015-02","2015-09","2011-01",83,[30],[715,716,728,715,716,728],"acarbose",{"trials":730,"activeCount":100},[],{"intervention":715,"totalTrials":33,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":756,"NA":766},{"trials":734,"activeCount":100},[],{"trials":736,"activeCount":100},[],{"trials":738,"activeCount":100},[],{"trials":740,"activeCount":100},[741,752],{"nctId":742,"briefTitle":743,"status":230,"phases":744,"primaryCompletion":745,"completion":746,"start":747,"enrollment":748,"conditions":749,"interventions":750},"NCT02623998","Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)",[91],"2018-09-01","2019-11-30","2016-07-09",102,[30],[715,751],"sitagliptin\u002Fmetformin",{"nctId":692,"briefTitle":693,"status":230,"phases":753,"primaryCompletion":695,"completion":696,"start":697,"enrollment":698,"conditions":754,"interventions":755},[91],[30],[701,702,669],{"trials":757,"activeCount":100},[758,762],{"nctId":706,"briefTitle":707,"status":230,"phases":759,"primaryCompletion":709,"completion":710,"start":711,"enrollment":712,"conditions":760,"interventions":761},[92],[30],[715,716,717],{"nctId":719,"briefTitle":720,"status":230,"phases":763,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":764,"interventions":765},[92],[30],[715,716,728,715,716,728],{"trials":767,"activeCount":100},[],{"intervention":769,"totalTrials":770,"cells":771},"Tranexamic Acid",3,{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":778,"PHASE4":806,"NA":817},{"trials":773,"activeCount":100},[],{"trials":775,"activeCount":100},[],{"trials":777,"activeCount":100},[],{"trials":779,"activeCount":100},[780,793],{"nctId":781,"briefTitle":782,"status":783,"phases":784,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":788,"interventions":792},"NCT03954314","DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery","TERMINATED",[91],"2023-11-28","2019-09-17",3242,[789,790,791],"Bleeding","Surgical Blood Loss","Seizures",[769],{"nctId":794,"briefTitle":795,"status":230,"phases":796,"primaryCompletion":797,"completion":798,"start":799,"enrollment":800,"conditions":801,"interventions":805},"NCT03505723","PeriOperative ISchemic Evaluation-3 Trial",[91],"2021-11-08","2023-02-03","2018-06-27",9535,[802,803,804],"Perioperative Bleeding","Venous Thrombosis","Arterial Thrombosis",[769],{"trials":807,"activeCount":100},[808],{"nctId":809,"briefTitle":810,"status":230,"phases":811,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":815,"interventions":816},"NCT03376061","Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery",[92],"2018-09-04","2017-12-21",97,[789,790],[769],{"trials":818,"activeCount":100},[],{"intervention":820,"totalTrials":770,"cells":821},"Cefazolin",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":828,"PHASE4":841,"NA":866},{"trials":823,"activeCount":100},[],{"trials":825,"activeCount":100},[],{"trials":827,"activeCount":100},[],{"trials":829,"activeCount":100},[830],{"nctId":831,"briefTitle":832,"status":230,"phases":833,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":837,"interventions":839},"NCT01002911","Prevention of Arrhythmia Device Infection Trial (PADIT Pilot)",[91],"2012-01","2009-12",500,[838],"Arrythmias",[840,820],"Cefazolin, Bacitracin, Cefalexin",{"trials":842,"activeCount":100},[843,854],{"nctId":844,"briefTitle":845,"status":230,"phases":846,"primaryCompletion":847,"completion":848,"start":661,"enrollment":849,"conditions":850,"interventions":852},"NCT01613092","Prevention of Arrhythmia Device Infection Trial (PADIT)",[92],"2013-11","2013-12",241,[851],"Arrhythmia",[853,820],"Incremental",{"nctId":855,"briefTitle":856,"status":230,"phases":857,"primaryCompletion":858,"completion":859,"start":860,"enrollment":861,"conditions":862,"interventions":864},"NCT03402945","Prevention of Infections in Cardiac Surgery (PICS) Prevena Study",[92],"2023-04-27","2024-10-17","2018-03-05",4107,[863],"Surgical Site Infections",[820,865],"Vancomycin",{"trials":867,"activeCount":100},[],{"intervention":643,"totalTrials":145,"cells":869},{"EARLY_PHASE1":870,"PHASE1":872,"PHASE2":874,"PHASE3":876,"PHASE4":878,"NA":888},{"trials":871,"activeCount":100},[],{"trials":873,"activeCount":100},[],{"trials":875,"activeCount":100},[],{"trials":877,"activeCount":100},[],{"trials":879,"activeCount":100},[880,884],{"nctId":634,"briefTitle":635,"status":230,"phases":881,"primaryCompletion":637,"completion":638,"start":639,"enrollment":640,"conditions":882,"interventions":883},[92],[32],[643,643,240,240],{"nctId":657,"briefTitle":658,"status":230,"phases":885,"primaryCompletion":660,"completion":660,"start":661,"enrollment":662,"conditions":886,"interventions":887},[92],[664],[643,240,240],{"trials":889,"activeCount":100},[],{"intervention":891,"totalTrials":145,"cells":892},"Amiodarone",{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":899,"PHASE4":912,"NA":923},{"trials":894,"activeCount":100},[],{"trials":896,"activeCount":100},[],{"trials":898,"activeCount":100},[],{"trials":900,"activeCount":100},[901],{"nctId":902,"briefTitle":903,"status":783,"phases":904,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":908,"interventions":911},"NCT01097330","Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia",[91],"2012-03","2010-08",12,[909,910],"Defibrillators, Implantable","Tachycardia, Ventricular",[891],{"trials":913,"activeCount":100},[914],{"nctId":915,"briefTitle":916,"status":783,"phases":917,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":921,"interventions":922},"NCT02341105","AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation",[92],"2018-01","2016-01",10,[15],[891],{"trials":924,"activeCount":100},[],{"intervention":853,"totalTrials":145,"cells":926},{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":931,"PHASE3":933,"PHASE4":935,"NA":950},{"trials":928,"activeCount":100},[],{"trials":930,"activeCount":100},[],{"trials":932,"activeCount":100},[],{"trials":934,"activeCount":100},[],{"trials":936,"activeCount":100},[937,941],{"nctId":844,"briefTitle":845,"status":230,"phases":938,"primaryCompletion":847,"completion":848,"start":661,"enrollment":849,"conditions":939,"interventions":940},[92],[851],[853,820],{"nctId":942,"briefTitle":845,"status":230,"phases":943,"primaryCompletion":944,"completion":944,"start":945,"enrollment":946,"conditions":947,"interventions":948},"NCT01628666",[92],"2017-09-08","2012-12",12814,[851],[853,949],"Conventional",{"trials":951,"activeCount":100},[],{"intervention":654,"totalTrials":96,"cells":953},{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":962,"NA":968},{"trials":955,"activeCount":100},[],{"trials":957,"activeCount":100},[],{"trials":959,"activeCount":100},[],{"trials":961,"activeCount":100},[],{"trials":963,"activeCount":100},[964],{"nctId":645,"briefTitle":646,"status":230,"phases":965,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":966,"interventions":967},[92],[15,18],[654,655],{"trials":969,"activeCount":100},[],{"intervention":971,"totalTrials":96,"cells":972},"Continued therapy with the prescribed oral anticoagulant",{"EARLY_PHASE1":973,"PHASE1":975,"PHASE2":977,"PHASE3":979,"PHASE4":981,"NA":993},{"trials":974,"activeCount":100},[],{"trials":976,"activeCount":100},[],{"trials":978,"activeCount":100},[],{"trials":980,"activeCount":100},[],{"trials":982,"activeCount":100},[983],{"nctId":984,"briefTitle":985,"status":255,"phases":986,"primaryCompletion":860,"completion":860,"start":987,"enrollment":100,"conditions":988,"interventions":992},"NCT02885545","The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial",[92],"2016-09",[989,990,991],"Chronic Kidney Disease","Acute Bleeding","Cerebrovascular Stroke",[971],{"trials":994,"activeCount":100},[],{"intervention":996,"totalTrials":96,"cells":997},"Candesartan\u002FHCT",{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1006,"NA":1017},{"trials":999,"activeCount":100},[],{"trials":1001,"activeCount":100},[],{"trials":1003,"activeCount":100},[],{"trials":1005,"activeCount":100},[],{"trials":1007,"activeCount":100},[1008],{"nctId":1009,"briefTitle":1010,"status":230,"phases":1011,"primaryCompletion":711,"completion":919,"start":1012,"enrollment":1013,"conditions":1014,"interventions":1015},"NCT00468923","Heart Outcomes Prevention Evaluation-3",[92],"2007-05",12705,[621,18],[996,1016],"Rosuvastatin",{"trials":1018,"activeCount":100},[],{"intervention":1016,"totalTrials":96,"cells":1020},{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1027,"PHASE4":1029,"NA":1035},{"trials":1022,"activeCount":100},[],{"trials":1024,"activeCount":100},[],{"trials":1026,"activeCount":100},[],{"trials":1028,"activeCount":100},[],{"trials":1030,"activeCount":100},[1031],{"nctId":1009,"briefTitle":1010,"status":230,"phases":1032,"primaryCompletion":711,"completion":919,"start":1012,"enrollment":1013,"conditions":1033,"interventions":1034},[92],[621,18],[996,1016],{"trials":1036,"activeCount":100},[],{"intervention":1038,"totalTrials":96,"cells":1039},"RABEprazole 20 Mg Oral Delayed Release",{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1046,"PHASE4":1048,"NA":1061},{"trials":1041,"activeCount":100},[],{"trials":1043,"activeCount":100},[],{"trials":1045,"activeCount":100},[],{"trials":1047,"activeCount":100},[],{"trials":1049,"activeCount":100},[1050],{"nctId":1051,"briefTitle":1052,"status":230,"phases":1053,"primaryCompletion":1054,"completion":1054,"start":1055,"enrollment":1056,"conditions":1057,"interventions":1059},"NCT04157881","A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy Volunteers",[92],"2022-01-18","2020-01-03",46,[15,1058],"Venous Thromboembolism",[1038,1060],"APO-Dabigatran 150mg",{"trials":1062,"activeCount":100},[],{"intervention":1060,"totalTrials":96,"cells":1064},{"EARLY_PHASE1":1065,"PHASE1":1067,"PHASE2":1069,"PHASE3":1071,"PHASE4":1073,"NA":1079},{"trials":1066,"activeCount":100},[],{"trials":1068,"activeCount":100},[],{"trials":1070,"activeCount":100},[],{"trials":1072,"activeCount":100},[],{"trials":1074,"activeCount":100},[1075],{"nctId":1051,"briefTitle":1052,"status":230,"phases":1076,"primaryCompletion":1054,"completion":1054,"start":1055,"enrollment":1056,"conditions":1077,"interventions":1078},[92],[15,1058],[1038,1060],{"trials":1080,"activeCount":100},[],{"intervention":1082,"totalTrials":96,"cells":1083},"Methylprednisolone",{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1090,"PHASE4":1092,"NA":1108},{"trials":1085,"activeCount":100},[],{"trials":1087,"activeCount":100},[],{"trials":1089,"activeCount":100},[],{"trials":1091,"activeCount":100},[],{"trials":1093,"activeCount":100},[1094],{"nctId":1095,"briefTitle":1096,"status":1097,"phases":1098,"primaryCompletion":1099,"completion":1100,"start":1101,"enrollment":1102,"conditions":1103,"interventions":1107},"NCT00427388","Steroids In caRdiac Surgery Trial (SIRS Trial)","UNKNOWN",[92],"2014-02","2014-08","2007-06",7507,[1104,1105,1106],"Cardiac Surgical Procedures","Cardiopulmonary Bypass","Systemic Inflammatory Response Syndrome",[1082],{"trials":1109,"activeCount":100},[],{"intervention":949,"totalTrials":96,"cells":1111},{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1118,"PHASE4":1120,"NA":1126},{"trials":1113,"activeCount":100},[],{"trials":1115,"activeCount":100},[],{"trials":1117,"activeCount":100},[],{"trials":1119,"activeCount":100},[],{"trials":1121,"activeCount":100},[1122],{"nctId":942,"briefTitle":845,"status":230,"phases":1123,"primaryCompletion":944,"completion":944,"start":945,"enrollment":946,"conditions":1124,"interventions":1125},[92],[851],[853,949],{"trials":1127,"activeCount":100},[],{"intervention":1129,"totalTrials":96,"cells":1130},"Flecainide",{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1137,"PHASE4":1139,"NA":1149},{"trials":1132,"activeCount":100},[],{"trials":1134,"activeCount":100},[],{"trials":1136,"activeCount":100},[],{"trials":1138,"activeCount":100},[],{"trials":1140,"activeCount":100},[1141],{"nctId":1142,"briefTitle":1143,"status":255,"phases":1144,"primaryCompletion":1145,"completion":50,"start":1146,"enrollment":100,"conditions":1147,"interventions":1148},"NCT06142604","Single Dose Flecainide for Early Sinus Rhythm Conversion of Perioperative Atrial Fibrillation After Noncardiac Surgery",[92],"2025-06-30","2024-07-01",[15,555],[1129],{"trials":1150,"activeCount":100},[],{"intervention":717,"totalTrials":96,"cells":1152},{"EARLY_PHASE1":1153,"PHASE1":1155,"PHASE2":1157,"PHASE3":1159,"PHASE4":1161,"NA":1167},{"trials":1154,"activeCount":100},[],{"trials":1156,"activeCount":100},[],{"trials":1158,"activeCount":100},[],{"trials":1160,"activeCount":100},[],{"trials":1162,"activeCount":100},[1163],{"nctId":706,"briefTitle":707,"status":230,"phases":1164,"primaryCompletion":709,"completion":710,"start":711,"enrollment":712,"conditions":1165,"interventions":1166},[92],[30],[715,716,717],{"trials":1168,"activeCount":100},[],{"intervention":728,"totalTrials":96,"cells":1170},{"EARLY_PHASE1":1171,"PHASE1":1173,"PHASE2":1175,"PHASE3":1177,"PHASE4":1179,"NA":1185},{"trials":1172,"activeCount":100},[],{"trials":1174,"activeCount":100},[],{"trials":1176,"activeCount":100},[],{"trials":1178,"activeCount":100},[],{"trials":1180,"activeCount":100},[1181],{"nctId":719,"briefTitle":720,"status":230,"phases":1182,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":1183,"interventions":1184},[92],[30],[715,716,728,715,716,728],{"trials":1186,"activeCount":100},[],{"intervention":865,"totalTrials":96,"cells":1188},{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1195,"PHASE4":1197,"NA":1203},{"trials":1190,"activeCount":100},[],{"trials":1192,"activeCount":100},[],{"trials":1194,"activeCount":100},[],{"trials":1196,"activeCount":100},[],{"trials":1198,"activeCount":100},[1199],{"nctId":855,"briefTitle":856,"status":230,"phases":1200,"primaryCompletion":858,"completion":859,"start":860,"enrollment":861,"conditions":1201,"interventions":1202},[92],[863],[820,865],{"trials":1204,"activeCount":100},[],{"intervention":162,"totalTrials":33,"cells":1206},{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1213,"PHASE4":1243,"NA":1245},{"trials":1208,"activeCount":100},[],{"trials":1210,"activeCount":100},[],{"trials":1212,"activeCount":100},[],{"trials":1214,"activeCount":100},[1215,1219,1230,1234],{"nctId":228,"briefTitle":229,"status":230,"phases":1216,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":1217,"interventions":1218},[91],[236,237],[162,239,240,217],{"nctId":1220,"briefTitle":1221,"status":230,"phases":1222,"primaryCompletion":1223,"completion":1223,"start":1224,"enrollment":1225,"conditions":1226,"interventions":1229},"NCT03310125","Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)",[91],"2023-07-26","2018-02-14",3209,[15,1227,1228],"Atrial Flutter","Myocardial Injury After Non-Cardiac Surgery",[162],{"nctId":287,"briefTitle":288,"status":230,"phases":1231,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":1232,"interventions":1233},[91],[294,295],[162,297,179,298],{"nctId":1235,"briefTitle":1236,"status":230,"phases":1237,"primaryCompletion":1238,"completion":1238,"start":1239,"enrollment":1240,"conditions":1241,"interventions":1242},"NCT02282098","Colchicine in Atrial Fibrillation to Prevent Stroke",[91],"2020-11-17","2014-11",80,[15,18],[162],{"trials":1244,"activeCount":100},[],{"trials":1246,"activeCount":100},[],{"intervention":1248,"totalTrials":145,"cells":1249},"Colchicine 0.6 mg",{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1277,"NA":1279},{"trials":1251,"activeCount":100},[],{"trials":1253,"activeCount":100},[],{"trials":1255,"activeCount":100},[],{"trials":1257,"activeCount":100},[1258,1268],{"nctId":1259,"briefTitle":1260,"status":230,"phases":1261,"primaryCompletion":1262,"completion":1262,"start":1263,"enrollment":1264,"conditions":1265,"interventions":1267},"NCT04160117","Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI Pilot)",[91],"2022-05-30","2020-01-14",202,[15,1266],"Recurrence",[1248],{"nctId":1269,"briefTitle":1270,"status":230,"phases":1271,"primaryCompletion":1272,"completion":723,"start":1273,"enrollment":192,"conditions":1274,"interventions":1276},"NCT01985425","Colchicine For Prevention of Perioperative Atrial Fibrillation in Patients Undergoing Thoracic Surgery Pilot Study",[91],"2015-04","2014-04",[15,1275],"Thoracic Surgery",[1248],{"trials":1278,"activeCount":100},[],{"trials":1280,"activeCount":100},[],{"intervention":1282,"totalTrials":96,"cells":1283},"Benznidazole",{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1288,"PHASE3":1290,"PHASE4":1305,"NA":1307},{"trials":1285,"activeCount":100},[],{"trials":1287,"activeCount":100},[],{"trials":1289,"activeCount":100},[],{"trials":1291,"activeCount":100},[1292],{"nctId":1293,"briefTitle":1294,"status":230,"phases":1295,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":1299,"conditions":1300,"interventions":1304},"NCT00123916","BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease",[91],"2015-07","2015-08","2004-11",2854,[1301,1302,1303],"Chagas Disease","Trypanosomiasis","Heart Disease",[1282],{"trials":1306,"activeCount":100},[],{"trials":1308,"activeCount":100},[],{"intervention":1310,"totalTrials":96,"cells":1311},"glulisine insulin, glargine insulin",{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1316,"PHASE3":1318,"PHASE4":1329,"NA":1331},{"trials":1313,"activeCount":100},[],{"trials":1315,"activeCount":100},[],{"trials":1317,"activeCount":100},[],{"trials":1319,"activeCount":100},[1320],{"nctId":1321,"briefTitle":1322,"status":230,"phases":1323,"primaryCompletion":1324,"completion":1324,"start":1325,"enrollment":836,"conditions":1326,"interventions":1328},"NCT00640991","REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study)",[91],"2010-06","2008-04",[1327,27,24],"Hyperglycemia",[1310],{"trials":1330,"activeCount":100},[],{"trials":1332,"activeCount":100},[],{"intervention":239,"totalTrials":96,"cells":1334},{"EARLY_PHASE1":1335,"PHASE1":1337,"PHASE2":1339,"PHASE3":1341,"PHASE4":1347,"NA":1349},{"trials":1336,"activeCount":100},[],{"trials":1338,"activeCount":100},[],{"trials":1340,"activeCount":100},[],{"trials":1342,"activeCount":100},[1343],{"nctId":228,"briefTitle":229,"status":230,"phases":1344,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":1345,"interventions":1346},[91],[236,237],[162,239,240,217],{"trials":1348,"activeCount":100},[],{"trials":1350,"activeCount":100},[],{"intervention":689,"totalTrials":96,"cells":1352},{"EARLY_PHASE1":1353,"PHASE1":1355,"PHASE2":1357,"PHASE3":1359,"PHASE4":1365,"NA":1367},{"trials":1354,"activeCount":100},[],{"trials":1356,"activeCount":100},[],{"trials":1358,"activeCount":100},[],{"trials":1360,"activeCount":100},[1361],{"nctId":680,"briefTitle":681,"status":230,"phases":1362,"primaryCompletion":683,"completion":684,"start":685,"enrollment":686,"conditions":1363,"interventions":1364},[91],[30],[689,690,669],{"trials":1366,"activeCount":100},[],{"trials":1368,"activeCount":100},[],{"intervention":690,"totalTrials":96,"cells":1370},{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1375,"PHASE3":1377,"PHASE4":1383,"NA":1385},{"trials":1372,"activeCount":100},[],{"trials":1374,"activeCount":100},[],{"trials":1376,"activeCount":100},[],{"trials":1378,"activeCount":100},[1379],{"nctId":680,"briefTitle":681,"status":230,"phases":1380,"primaryCompletion":683,"completion":684,"start":685,"enrollment":686,"conditions":1381,"interventions":1382},[91],[30],[689,690,669],{"trials":1384,"activeCount":100},[],{"trials":1386,"activeCount":100},[],{"intervention":251,"totalTrials":96,"cells":1388},{"EARLY_PHASE1":1389,"PHASE1":1391,"PHASE2":1393,"PHASE3":1395,"PHASE4":1401,"NA":1403},{"trials":1390,"activeCount":100},[],{"trials":1392,"activeCount":100},[],{"trials":1394,"activeCount":100},[],{"trials":1396,"activeCount":100},[1397],{"nctId":242,"briefTitle":243,"status":230,"phases":1398,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":1399,"interventions":1400},[91],[249],[217,251],{"trials":1402,"activeCount":100},[],{"trials":1404,"activeCount":100},[],{"intervention":1406,"totalTrials":96,"cells":1407},"Rivaroxaban 2.5 Mg Oral Tablet bid",{"EARLY_PHASE1":1408,"PHASE1":1410,"PHASE2":1412,"PHASE3":1414,"PHASE4":1427,"NA":1429},{"trials":1409,"activeCount":100},[],{"trials":1411,"activeCount":100},[],{"trials":1413,"activeCount":100},[],{"trials":1415,"activeCount":100},[1416],{"nctId":1417,"briefTitle":1418,"status":230,"phases":1419,"primaryCompletion":1420,"completion":1420,"start":1421,"enrollment":1422,"conditions":1423,"interventions":1425},"NCT04142125","Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease",[91],"2023-09-18","2020-02-03",101,[35,1424],"Intracranial Atherosclerotic Disease",[1406,1426],"Acetylsalicyclic acid 81 mg tablet qd",{"trials":1428,"activeCount":100},[],{"trials":1430,"activeCount":100},[],{"intervention":1426,"totalTrials":96,"cells":1432},{"EARLY_PHASE1":1433,"PHASE1":1435,"PHASE2":1437,"PHASE3":1439,"PHASE4":1445,"NA":1447},{"trials":1434,"activeCount":100},[],{"trials":1436,"activeCount":100},[],{"trials":1438,"activeCount":100},[],{"trials":1440,"activeCount":100},[1441],{"nctId":1417,"briefTitle":1418,"status":230,"phases":1442,"primaryCompletion":1420,"completion":1420,"start":1421,"enrollment":1422,"conditions":1443,"interventions":1444},[91],[35,1424],[1406,1426],{"trials":1446,"activeCount":100},[],{"trials":1448,"activeCount":100},[],{"intervention":1450,"totalTrials":96,"cells":1451},"Spironolactone 25Mg",{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1456,"PHASE3":1458,"PHASE4":1470,"NA":1472},{"trials":1453,"activeCount":100},[],{"trials":1455,"activeCount":100},[],{"trials":1457,"activeCount":100},[],{"trials":1459,"activeCount":100},[1460],{"nctId":1461,"briefTitle":1462,"status":230,"phases":1463,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":1466,"conditions":1467,"interventions":1469},"NCT03020303","Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease",[91],"2025-03-14","2017-07-07",2538,[1468],"Endstage Renal Disease",[1450],{"trials":1471,"activeCount":100},[],{"trials":1473,"activeCount":100},[],{"intervention":1475,"totalTrials":96,"cells":1476},"Gabapentin",{"EARLY_PHASE1":1477,"PHASE1":1479,"PHASE2":1481,"PHASE3":1483,"PHASE4":1498,"NA":1500},{"trials":1478,"activeCount":100},[],{"trials":1480,"activeCount":100},[],{"trials":1482,"activeCount":100},[],{"trials":1484,"activeCount":100},[1485],{"nctId":1486,"briefTitle":1487,"status":230,"phases":1488,"primaryCompletion":1489,"completion":1490,"start":1491,"enrollment":1492,"conditions":1493,"interventions":1496},"NCT03806530","DIalysis Symptom COntrol-Restless Legs Syndrome Trial",[91],"2021-12-14","2022-07-19","2019-05-01",52,[1494,1495],"End Stage Renal Disease","Restless Legs Syndrome",[1475,1497],"Ropinirole",{"trials":1499,"activeCount":100},[],{"trials":1501,"activeCount":100},[],{"intervention":1497,"totalTrials":96,"cells":1503},{"EARLY_PHASE1":1504,"PHASE1":1506,"PHASE2":1508,"PHASE3":1510,"PHASE4":1516,"NA":1518},{"trials":1505,"activeCount":100},[],{"trials":1507,"activeCount":100},[],{"trials":1509,"activeCount":100},[],{"trials":1511,"activeCount":100},[1512],{"nctId":1486,"briefTitle":1487,"status":230,"phases":1513,"primaryCompletion":1489,"completion":1490,"start":1491,"enrollment":1492,"conditions":1514,"interventions":1515},[91],[1494,1495],[1475,1497],{"trials":1517,"activeCount":100},[],{"trials":1519,"activeCount":100},[],{"intervention":297,"totalTrials":96,"cells":1521},{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1528,"PHASE4":1534,"NA":1536},{"trials":1523,"activeCount":100},[],{"trials":1525,"activeCount":100},[],{"trials":1527,"activeCount":100},[],{"trials":1529,"activeCount":100},[1530],{"nctId":287,"briefTitle":288,"status":230,"phases":1531,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":1532,"interventions":1533},[91],[294,295],[162,297,179,298],{"trials":1535,"activeCount":100},[],{"trials":1537,"activeCount":100},[],{"intervention":298,"totalTrials":96,"cells":1539},{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1544,"PHASE3":1546,"PHASE4":1552,"NA":1554},{"trials":1541,"activeCount":100},[],{"trials":1543,"activeCount":100},[],{"trials":1545,"activeCount":100},[],{"trials":1547,"activeCount":100},[1548],{"nctId":287,"briefTitle":288,"status":230,"phases":1549,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":1550,"interventions":1551},[91],[294,295],[162,297,179,298],{"trials":1553,"activeCount":100},[],{"trials":1555,"activeCount":100},[],{"intervention":625,"totalTrials":96,"cells":1557},{"EARLY_PHASE1":1558,"PHASE1":1560,"PHASE2":1562,"PHASE3":1564,"PHASE4":1570,"NA":1572},{"trials":1559,"activeCount":100},[],{"trials":1561,"activeCount":100},[],{"trials":1563,"activeCount":100},[],{"trials":1565,"activeCount":100},[1566],{"nctId":613,"briefTitle":614,"status":230,"phases":1567,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":1568,"interventions":1569},[91],[621,622,623],[625,240,626],{"trials":1571,"activeCount":100},[],{"trials":1573,"activeCount":100},[],{"intervention":626,"totalTrials":96,"cells":1575},{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1582,"PHASE4":1588,"NA":1590},{"trials":1577,"activeCount":100},[],{"trials":1579,"activeCount":100},[],{"trials":1581,"activeCount":100},[],{"trials":1583,"activeCount":100},[1584],{"nctId":613,"briefTitle":614,"status":230,"phases":1585,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":1586,"interventions":1587},[91],[621,622,623],[625,240,626],{"trials":1589,"activeCount":100},[],{"trials":1591,"activeCount":100},[],{"intervention":1593,"totalTrials":96,"cells":1594},"tissue plasminogen activator",{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1599,"PHASE3":1601,"PHASE4":1613,"NA":1615},{"trials":1596,"activeCount":100},[],{"trials":1598,"activeCount":100},[],{"trials":1600,"activeCount":100},[],{"trials":1602,"activeCount":100},[1603],{"nctId":1604,"briefTitle":1605,"status":230,"phases":1606,"primaryCompletion":1607,"completion":1608,"start":1609,"enrollment":1610,"conditions":1611,"interventions":1612},"NCT03335839","Adjunctive, Low-dose tPA in Primary PCI for STEMI",[91],"2024-09-17","2025-02-12","2018-04-01",210,[24,577],[1593],{"trials":1614,"activeCount":100},[],{"trials":1616,"activeCount":100},[],{"intervention":1618,"totalTrials":96,"cells":1619},"NMDA active",{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1624,"PHASE3":1626,"PHASE4":1641,"NA":1643},{"trials":1621,"activeCount":100},[],{"trials":1623,"activeCount":100},[],{"trials":1625,"activeCount":100},[],{"trials":1627,"activeCount":100},[1628],{"nctId":1629,"briefTitle":1630,"status":783,"phases":1631,"primaryCompletion":710,"completion":1632,"start":1633,"enrollment":1634,"conditions":1635,"interventions":1637},"NCT02950233","Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial",[91],"2019-03-31","2017-05-04",27,[1636],"Pain, Postoperative",[1618,1638,1639,1640],"Steroid active","NMDA placebo","Steroid placebo",{"trials":1642,"activeCount":100},[],{"trials":1644,"activeCount":100},[],{"intervention":1638,"totalTrials":96,"cells":1646},{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1653,"PHASE4":1659,"NA":1661},{"trials":1648,"activeCount":100},[],{"trials":1650,"activeCount":100},[],{"trials":1652,"activeCount":100},[],{"trials":1654,"activeCount":100},[1655],{"nctId":1629,"briefTitle":1630,"status":783,"phases":1656,"primaryCompletion":710,"completion":1632,"start":1633,"enrollment":1634,"conditions":1657,"interventions":1658},[91],[1636],[1618,1638,1639,1640],{"trials":1660,"activeCount":100},[],{"trials":1662,"activeCount":100},[],{"intervention":1639,"totalTrials":96,"cells":1664},{"EARLY_PHASE1":1665,"PHASE1":1667,"PHASE2":1669,"PHASE3":1671,"PHASE4":1677,"NA":1679},{"trials":1666,"activeCount":100},[],{"trials":1668,"activeCount":100},[],{"trials":1670,"activeCount":100},[],{"trials":1672,"activeCount":100},[1673],{"nctId":1629,"briefTitle":1630,"status":783,"phases":1674,"primaryCompletion":710,"completion":1632,"start":1633,"enrollment":1634,"conditions":1675,"interventions":1676},[91],[1636],[1618,1638,1639,1640],{"trials":1678,"activeCount":100},[],{"trials":1680,"activeCount":100},[],{"intervention":1640,"totalTrials":96,"cells":1682},{"EARLY_PHASE1":1683,"PHASE1":1685,"PHASE2":1687,"PHASE3":1689,"PHASE4":1695,"NA":1697},{"trials":1684,"activeCount":100},[],{"trials":1686,"activeCount":100},[],{"trials":1688,"activeCount":100},[],{"trials":1690,"activeCount":100},[1691],{"nctId":1629,"briefTitle":1630,"status":783,"phases":1692,"primaryCompletion":710,"completion":1632,"start":1633,"enrollment":1634,"conditions":1693,"interventions":1694},[91],[1636],[1618,1638,1639,1640],{"trials":1696,"activeCount":100},[],{"trials":1698,"activeCount":100},[],{"intervention":1700,"totalTrials":96,"cells":1701},"Conventional Antiarrhythmic Drug Therapy",{"EARLY_PHASE1":1702,"PHASE1":1704,"PHASE2":1706,"PHASE3":1708,"PHASE4":1719,"NA":1721},{"trials":1703,"activeCount":100},[],{"trials":1705,"activeCount":100},[],{"trials":1707,"activeCount":100},[],{"trials":1709,"activeCount":100},[1710],{"nctId":1711,"briefTitle":1712,"status":230,"phases":1713,"primaryCompletion":1714,"completion":1714,"start":1715,"enrollment":1716,"conditions":1717,"interventions":1718},"NCT00392054","First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)",[91],"2012-02","2006-08",127,[15],[1700],{"trials":1720,"activeCount":100},[],{"trials":1722,"activeCount":100},[],{"intervention":751,"totalTrials":96,"cells":1724},{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1729,"PHASE3":1731,"PHASE4":1737,"NA":1739},{"trials":1726,"activeCount":100},[],{"trials":1728,"activeCount":100},[],{"trials":1730,"activeCount":100},[],{"trials":1732,"activeCount":100},[1733],{"nctId":742,"briefTitle":743,"status":230,"phases":1734,"primaryCompletion":745,"completion":746,"start":747,"enrollment":748,"conditions":1735,"interventions":1736},[91],[30],[715,751],{"trials":1738,"activeCount":100},[],{"trials":1740,"activeCount":100},[],{"intervention":840,"totalTrials":96,"cells":1742},{"EARLY_PHASE1":1743,"PHASE1":1745,"PHASE2":1747,"PHASE3":1749,"PHASE4":1755,"NA":1757},{"trials":1744,"activeCount":100},[],{"trials":1746,"activeCount":100},[],{"trials":1748,"activeCount":100},[],{"trials":1750,"activeCount":100},[1751],{"nctId":831,"briefTitle":832,"status":230,"phases":1752,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":1753,"interventions":1754},[91],[838],[840,820],{"trials":1756,"activeCount":100},[],{"trials":1758,"activeCount":100},[],{"intervention":701,"totalTrials":96,"cells":1760},{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1765,"PHASE3":1767,"PHASE4":1773,"NA":1775},{"trials":1762,"activeCount":100},[],{"trials":1764,"activeCount":100},[],{"trials":1766,"activeCount":100},[],{"trials":1768,"activeCount":100},[1769],{"nctId":692,"briefTitle":693,"status":230,"phases":1770,"primaryCompletion":695,"completion":696,"start":697,"enrollment":698,"conditions":1771,"interventions":1772},[91],[30],[701,702,669],{"trials":1774,"activeCount":100},[],{"trials":1776,"activeCount":100},[],{"intervention":1778,"totalTrials":96,"cells":1779},"Dabigatran",{"EARLY_PHASE1":1780,"PHASE1":1782,"PHASE2":1784,"PHASE3":1786,"PHASE4":1799,"NA":1801},{"trials":1781,"activeCount":100},[],{"trials":1783,"activeCount":100},[],{"trials":1785,"activeCount":100},[],{"trials":1787,"activeCount":100},[1788],{"nctId":1789,"briefTitle":1790,"status":230,"phases":1791,"primaryCompletion":1792,"completion":1792,"start":1793,"enrollment":1794,"conditions":1795,"interventions":1797},"NCT01661101","Management of Myocardial Injury After Noncardiac Surgery Trial",[91],"2018-03-01","2013-01",1754,[1796],"Myocardial Injury After Noncardiac Surgery (MINS)",[1778,1798],"Omeprazole",{"trials":1800,"activeCount":100},[],{"trials":1802,"activeCount":100},[],{"intervention":1798,"totalTrials":96,"cells":1804},{"EARLY_PHASE1":1805,"PHASE1":1807,"PHASE2":1809,"PHASE3":1811,"PHASE4":1817,"NA":1819},{"trials":1806,"activeCount":100},[],{"trials":1808,"activeCount":100},[],{"trials":1810,"activeCount":100},[],{"trials":1812,"activeCount":100},[1813],{"nctId":1789,"briefTitle":1790,"status":230,"phases":1814,"primaryCompletion":1792,"completion":1792,"start":1793,"enrollment":1794,"conditions":1815,"interventions":1816},[91],[1796],[1778,1798],{"trials":1818,"activeCount":100},[],{"trials":1820,"activeCount":100},[],{"intervention":1822,"totalTrials":96,"cells":1823},"Colchicine Pill",{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1828,"PHASE3":1838,"PHASE4":1840,"NA":1842},{"trials":1825,"activeCount":100},[],{"trials":1827,"activeCount":100},[],{"trials":1829,"activeCount":100},[1830],{"nctId":1831,"briefTitle":1832,"status":230,"phases":1833,"primaryCompletion":1834,"completion":1834,"start":1835,"enrollment":192,"conditions":1836,"interventions":1837},"NCT05159219","Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage",[90],"2024-12-03","2022-08-04",[115],[1822],{"trials":1839,"activeCount":100},[],{"trials":1841,"activeCount":100},[],{"trials":1843,"activeCount":100},[],{"intervention":1845,"totalTrials":96,"cells":1846},"NOAC",{"EARLY_PHASE1":1847,"PHASE1":1849,"PHASE2":1851,"PHASE3":1865,"PHASE4":1867,"NA":1869},{"trials":1848,"activeCount":100},[],{"trials":1850,"activeCount":100},[],{"trials":1852,"activeCount":100},[1853],{"nctId":1854,"briefTitle":1855,"status":230,"phases":1856,"primaryCompletion":1857,"completion":1858,"start":1859,"enrollment":1860,"conditions":1861,"interventions":1863},"NCT02998905","NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH",[90],"2019-10-31","2020-02-18","2017-04-26",30,[15,1862],"Intracerebral Hemorrhage",[1845,1864],"Acetylsalicylic Acid",{"trials":1866,"activeCount":100},[],{"trials":1868,"activeCount":100},[],{"trials":1870,"activeCount":100},[],{"intervention":1864,"totalTrials":96,"cells":1872},{"EARLY_PHASE1":1873,"PHASE1":1875,"PHASE2":1877,"PHASE3":1883,"PHASE4":1885,"NA":1887},{"trials":1874,"activeCount":100},[],{"trials":1876,"activeCount":100},[],{"trials":1878,"activeCount":100},[1879],{"nctId":1854,"briefTitle":1855,"status":230,"phases":1880,"primaryCompletion":1857,"completion":1858,"start":1859,"enrollment":1860,"conditions":1881,"interventions":1882},[90],[15,1862],[1845,1864],{"trials":1884,"activeCount":100},[],{"trials":1886,"activeCount":100},[],{"trials":1888,"activeCount":100},[],{"intervention":1890,"totalTrials":96,"cells":1891},"Alirocumab",{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1896,"PHASE3":1912,"PHASE4":1914,"NA":1916},{"trials":1893,"activeCount":100},[],{"trials":1895,"activeCount":100},[],{"trials":1897,"activeCount":100},[1898],{"nctId":1899,"briefTitle":1900,"status":230,"phases":1901,"primaryCompletion":1902,"completion":1903,"start":1904,"enrollment":814,"conditions":1905,"interventions":1911},"NCT03718286","Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI",[90],"2021-06-30","2021-10-08","2019-03-11",[294,1906,1907,1908,1909,1910],"Acute Coronary Syndrome","Hypercholesterolemia","Hyperlipidemias","Dyslipidemias","Physiological Effects of Drugs",[1890],{"trials":1913,"activeCount":100},[],{"trials":1915,"activeCount":100},[],{"trials":1917,"activeCount":100},[],{"intervention":1919,"totalTrials":96,"cells":1920},"standard-of-care treatments for LV impairment",{"EARLY_PHASE1":1921,"PHASE1":1923,"PHASE2":1933,"PHASE3":1935,"PHASE4":1937,"NA":1939},{"trials":1922,"activeCount":100},[],{"trials":1924,"activeCount":100},[1925],{"nctId":1926,"briefTitle":1927,"status":230,"phases":1928,"primaryCompletion":1929,"completion":1929,"start":1930,"enrollment":11,"conditions":1931,"interventions":1932},"NCT02907021","Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2",[89],"2018-04-12","2016-11-01",[21,471],[1919],{"trials":1934,"activeCount":100},[],{"trials":1936,"activeCount":100},[],{"trials":1938,"activeCount":100},[],{"trials":1940,"activeCount":100},[]]